Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative Dapagliflozin in T2DM Cardiac Surgery
NCT05621551Phase 4Completed
- Sponsor
- National Center for Cardiovascular Disease
- Start
- Nov 2022
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in type 2 diabetes mellitus (T2DM) comparing Dapagliflozin with Standard of care (2 arms). Primary endpoint: High-sensitivity Troponin I at 2 days. Started Nov 2022; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05621551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05621551.